An observational study in Borrelia Infections, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by University Hospital, Strasbourg, France · Observational
Among 13 studies in Lyme Disease with a site in France — 5 open to participants now, 5 under way, none of them phase 3. Lyme Disease · France.
Among the 13 studies in Lyme Disease with a site in France, this one is one of 3 that started in 2025, is one of 9 observational ones, and was the 11th registered.
97 studies on the registry are indexed under Lyme Disease; 26 are open to participants now.
Browse Lyme Disease studies →5 of the 13 studies in Lyme Disease with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
University Hospital, Strasbourg, France · Sites in France
University Hospital, Montpellier · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 100 is below the median of 400 across 42 observational studies indexed under Lyme Disease.
Median enrollment 56 across the 4 interventional studies, 100 across the 9 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 7 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.
University Hospital, Strasbourg, France has 7 studies filed under Lyme Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Lyme Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05641116Centre Hospitalier Universitaire de Saint EtienneEffectiveness of an Intervention Combining Adapted Physical Activity and Therapeutic Education in Patients With Chronic Symptoms Attributed to Lyme Borreliosis. | 2026-12 |
Among the 13 studies in Lyme Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical, biological, radiological, and pharmacological description of cases of disseminated borreliosis (Borrelia burgdorferi sl. and Borrelia miyamotoi) occurring in patients who received drug treatment based on anti-CD20 monoclonal antibodies.
Patient having presented disseminated borreliosis confirmed by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi) within 24 months of receiving treatment with an anti-CD20 monoclonal antibody between January 1, 2010, and July 30, 2025.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Refusal to participate in the study
Description of the clinical presentation of cases of disseminated borreliosis occurring in patients receiving anti-CD20 therapy in France
The clinical presentation describes how the disease manifests in patients: * the symptoms, * their severity, * and their progression. Example: Two patients may have the same disease, but one will primarily experience fever while the other will have neurological symptoms. This is part of the clinical presentation.
Time frame: Up to 12 months
Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →